Article ; Online: Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review.
2024 Volume 29, Issue 1, Page(s) e13057
Abstract: Background: Helicobacter pylori antibiotic resistance has undergone vast changes in the last two decades. No systematic review has been done on the prevalence of antibiotic resistant H. pylori in India in the last two decades. We evaluated the pattern ... ...
Abstract | Background: Helicobacter pylori antibiotic resistance has undergone vast changes in the last two decades. No systematic review has been done on the prevalence of antibiotic resistant H. pylori in India in the last two decades. We evaluated the pattern of resistance rates across various regions of India. Materials and methods: A systematic review of the geographical variations in antibiotic resistance pattern of H. pylori was conducted using PubMed, Google Scholar, Web of Science, Science Direct, etc. for articles published between January 1, 2000 and May 30, 2023. Random effects-model-based Cochran's Q test, I Results: The overall resistance was highest against metronidazole (77.65%) followed by amoxicillin (37.78%), levofloxacin (32.8%), clarithromycin (35.64%), furazolidone (12.03%), and tetracycline (11.63%). 14.7% of the H. pylori isolates were multi-drug resistant. Under meta-analysis of each antibiotic, high heterogeneity levels were observed having I Conclusions: Metronidazole resistance is high in most regions of India except Assam and Mumbai while clarithromycin is found to be ineffective in South India, Gujarat, and Kashmir. As compared to other antibiotics, resistance to amoxicillin is generally low except in certain regions (Hyderabad, Chennai, and the Gangetic belt of North India). Tetracycline and Furazolidone have the least resistance rates and should be part of anti- H. pylori regimens. The resurgence of high single and multidrug resistance to the commonly used drugs suggests the need for newer antibiotics and regular resistance surveillance studies. |
---|---|
MeSH term(s) | Humans ; Metronidazole/pharmacology ; Metronidazole/therapeutic use ; Clarithromycin ; Helicobacter pylori ; Levofloxacin ; Furazolidone ; India/epidemiology ; Helicobacter Infections/drug therapy ; Helicobacter Infections/epidemiology ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Amoxicillin ; Tetracycline ; Antibodies ; Drug Resistance, Microbial |
Chemical Substances | Metronidazole (140QMO216E) ; Clarithromycin (H1250JIK0A) ; Levofloxacin (6GNT3Y5LMF) ; Furazolidone (5J9CPU3RE0) ; Anti-Bacterial Agents ; Amoxicillin (804826J2HU) ; Tetracycline (F8VB5M810T) ; Antibodies |
Language | English |
Publishing date | 2024-02-28 |
Publishing country | England |
Document type | Systematic Review ; Meta-Analysis ; Journal Article ; Review |
ZDB-ID | 1330665-0 |
ISSN | 1523-5378 ; 1083-4389 |
ISSN (online) | 1523-5378 |
ISSN | 1083-4389 |
DOI | 10.1111/hel.13057 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 4801: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.